Transportability of two heart failure trials to a disease registry using individual patient data.

Lili Wei,David M Phillippo,Anoop Shah,John Gf Cleland,Jim Lewsey,David A McAllister,David M. Phillippo,John GF. Cleland,David A. McAllister

DOI: https://doi.org/10.1016/j.jclinepi.2023.08.019

IF: 7.407

2023-09-02

Journal of Clinical Epidemiology

Abstract:Objective RCTs are the gold-standard for determining therapeutic efficacy, but are often unrepresentative of real-world settings. Statistical transportation-methods (hereafter transportation) can partially account for these differences, improving trial applicability without breaking randomisation. We transported treatment effects from two heart failure (HF) trials to a HF registry. Study Design and Setting Individual-patient-level data from two trials (COMET, comparing carvedilol and metoprolol, and DIG, comparing digoxin and placebo) and a Scottish HF registry were obtained. The primary endpoint for both trials was all-cause mortality; secondary outcomes were all-cause mortality/hospitalisation for COMET and HF-related death or hospitalisation for DIG. We performed transportation using regression-based and inverse odds of sampling weights (IOSW) approaches. Results Registry patients were older, had poorer renal function and received higher-doses of loop-diuretics than trial participants. For each trial, point estimates were similar for the original and IOSW (e.g., DIG composite outcome: OR 0.75 (0.69, 0.82) versus 0.73 (0.64, 0.83)). Treatment effect estimates were also similar when examining high-risk (0.64 (0.46, 0.89)) and low-risk registry patients (0.73 (0.61, 0.86)). Similar results were obtained using regression-based transportation. Conclusion Regression-based or IOSW approaches can be used to transport trial effect estimates to patients administrative/registry data, with only moderate reductions in precision.

public, environmental & occupational health,health care sciences & services